Related Experiment Video
Updated: May 24, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Biosimilars: current perspectives and future implications.
1Department of Pharmacology, Jawaharlal Nehru Medical College, Aligarh Muslim University, Aligarh, Uttar Pradesh, India. drmonikamisra@gmail.com
Indian Journal of Pharmacology
|February 21, 2012
Summary
Biosimilars are not biological generics due to manufacturing complexities. This article explores biosimilar differences, safety concerns, and regulatory needs for these unique biological products.
Area of Science:
- Biopharmaceutical Science
- Regulatory Affairs
Background:
- Biosimilars are biological products highly similar to innovator biopharmaceuticals, developed post-patent expiration.
- Unlike chemical generics, biosimilars are unique molecules with limited initial approval data, raising safety and efficacy questions.
Purpose of the Study:
- To differentiate biosimilars from chemical generics.
- To examine concerns regarding biosimilar safety and efficacy.
- To highlight the necessity for appropriate biosimilar approval regulations.
Main Methods:
- Comparative analysis of biosimilar and chemical generic characteristics.
- Review of existing literature on biosimilar safety and efficacy data.
- Examination of regulatory frameworks for biosimilar approval.
Main Results:
- Biosimilars possess distinct structural and manufacturing complexities compared to chemical generics.
- Limited initial data for biosimilars necessitates careful consideration of safety and efficacy.
- The unique nature of biosimilars demands specific regulatory pathways.
Conclusions:
- Biosimilars should not be equated with biological generics due to inherent complexities.
- Addressing safety and efficacy concerns is crucial for biosimilar adoption.
- Robust and specific regulatory guidelines are essential for approving biosimilars.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...